Financial Review: Iovance Biotherapeutics (IOVA) vs. The Competition

Iovance Biotherapeutics (NASDAQ:IOVA) is one of 846 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Iovance Biotherapeutics to similar businesses based on the strength of its earnings, institutional ownership, valuation, analyst recommendations, dividends, profitability and risk.

Valuation & Earnings

This table compares Iovance Biotherapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Iovance Biotherapeutics	$378.98 million	-$390.98 million	-15.26
Iovance Biotherapeutics Competitors	$722.00 million	$11.43 million	-14.85

Iovance Biotherapeutics’ rivals have higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Iovance Biotherapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics’ rivals have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Institutional & Insider Ownership

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Iovance Biotherapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1	3	9	1	2.71
Iovance Biotherapeutics Competitors	9904	15273	45596	1593	2.54

Iovance Biotherapeutics presently has a consensus price target of $13.80, suggesting a potential upside of 70.58%. As a group, “Biotechnology” companies have a potential upside of 99.41%. Given Iovance Biotherapeutics’ rivals higher possible upside, analysts clearly believe Iovance Biotherapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Iovance Biotherapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-58.20%	-29.71%	-23.55%
Iovance Biotherapeutics Competitors	-12,285.98%	-196.04%	-30.61%

Summary

Iovance Biotherapeutics beats its rivals on 7 of the 13 factors compared.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient. The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.